{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:06:26Z","timestamp":1771603586407,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bcmd.2021.102591","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:45:10Z","timestamp":1625100310000},"page":"102591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5\u00a0years of treatment"],"prefix":"10.1016","volume":"90","author":[{"given":"Livia d'\u00c1vila","family":"Paskulin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Tzovenos","family":"Starosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9bora","family":"Bertholdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo Pinto","family":"Vairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Vedolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Vanessa Doederlein","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9645","key":"10.1016\/j.bcmd.2021.102591_bb0005","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher&apos;s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcmd.2021.102591_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2021.102591_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \"simple\" disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.bcmd.2021.102591_bb0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","article-title":"Skeletal complications of Gaucher disease","volume":"64","author":"Stowens","year":"1985","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.bcmd.2021.102591_bb0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1008859420641","article-title":"Quality of life assessment in adults with type 1 Gaucher disease","volume":"8","author":"Masek","year":"1999","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102591_bb0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","article-title":"Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients","volume":"22","author":"Vom Dahl","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102591_bb0035","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: from pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bcmd.2021.102591_bb0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.15402","article-title":"How we manage Gaucher disease in the era of choices","volume":"182","author":"Revel-Vilk","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"4 Suppl 5","key":"10.1016\/j.bcmd.2021.102591_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"issue":"23","key":"10.1016\/j.bcmd.2021.102591_bb0050","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2021.102591_bb0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2014.02.006","article-title":"Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up","volume":"53","author":"Elstein","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2021.102591_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: an expert consensus document from the european working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102591_bb0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2106\/00004623-198668060-00002","article-title":"Evaluation of Gaucher disease using magnetic resonance imaging","volume":"68","author":"Rosenthal","year":"1986","journal-title":"J. Bone Joint Surg. Am."},{"issue":"9","key":"10.1016\/j.bcmd.2021.102591_bb0070","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","article-title":"Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results","volume":"30","author":"Poll","year":"2001","journal-title":"Skelet. Radiol."},{"issue":"10","key":"10.1016\/j.bcmd.2021.102591_bb0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s002560000276","article-title":"Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume","volume":"29","author":"Terk","year":"2000","journal-title":"Skelet. Radiol."},{"issue":"4","key":"10.1016\/j.bcmd.2021.102591_bb0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0022-2143(96)90183-3","article-title":"Analysis of the lipids of normal and Gaucher bone marrow","volume":"127","author":"Miller","year":"1996","journal-title":"J. Lab. Clin. Med."},{"issue":"5","key":"10.1016\/j.bcmd.2021.102591_bb0085","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00004728-200209000-00031","article-title":"Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease","volume":"26","author":"Vlieger","year":"2002","journal-title":"J. Comput. Assist. Tomogr."},{"issue":"2","key":"10.1016\/j.bcmd.2021.102591_bb0090","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2013initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.bcmd.2021.102591_bb0095","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00330-015-3715-2","article-title":"Bone marrow involvement in Gaucher disease at MRI: what long-term evolution can we expect under enzyme replacement therapy?","volume":"25","author":"Fedida","year":"2015","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.bcmd.2021.102591_bb0100","series-title":"PCDT - Protocolo de Diretrizes Cl\u00ednicas e Terap\u00eauticas para Doen\u00e7a de Gaucher","first-page":"1","author":"Figueiredo","year":"2017"},{"issue":"1","key":"10.1016\/j.bcmd.2021.102591_bb0105","first-page":"25","article-title":"Usefulness of bone mineral density measurement in menopausal woman: a study of 217 post menopausal women","volume":"30","author":"Ansari","year":"2004","journal-title":"Bangladesh Med. Res. Counc. Bull."},{"key":"10.1016\/j.bcmd.2021.102591_bb0110","series-title":"Adult Official Positions of the International Society for Clinical Densitometry","author":"Board","year":"2019"},{"issue":"6","key":"10.1016\/j.bcmd.2021.102591_bb0115","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10545-014-9726-3","article-title":"Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned","volume":"37","author":"van Dussen","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2021.102591_bb0120","first-page":"100544","article-title":"Rare GBA1 genotype associated with severe bone disease in Gaucher disease type 1","volume":"21","author":"d'Avila Paskulin","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.bcmd.2021.102591_bb0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiology.153.1.6089263","article-title":"Simple proton spectroscopic imaging","volume":"153","author":"Dixon","year":"1984","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.bcmd.2021.102591_bb0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiology.210.1.r99ja35189","article-title":"Uniform fat suppression in hands and feet through the use of two-point Dixon chemical shift MR imaging","volume":"210","author":"Maas","year":"1999","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.bcmd.2021.102591_bb0135","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcmd.2021.102591_bb0140","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.bcmd.2021.102591_bb0145","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"van Dussen","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2021.102591_bb0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J Rare Dis"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:12Z","timestamp":1761050172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979621000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"alternative-id":["S1079979621000577"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102591","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5\u00a0years of treatment","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102591"}}